Search Results
Teresa Elo
Teresa Elo
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Teresa Elo in
Google Scholar
PubMed
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Teresa Elo in
Google Scholar
PubMed
Lan Yu
Lan Yu
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Lan Yu in
Google Scholar
PubMed
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Lan Yu in
Google Scholar
PubMed
Eeva Valve
Eeva Valve
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Eeva Valve in
Google Scholar
PubMed
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Eeva Valve in
Google Scholar
PubMed
Sari Mäkelä
Sari Mäkelä
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Sari Mäkelä in
Google Scholar
PubMed
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Sari Mäkelä in
Google Scholar
PubMed
Pirkko Härkönen
Pirkko Härkönen
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Pirkko Härkönen in
Google Scholar
PubMed
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Departments of Cell Biology and Anatomy
Pharmacology Drug Development and Therapeutics
Turku Center for Disease Modeling Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
Functional Foods Forum University of Turku, Turku, Finland
Department of Laboratory Medicine MAS University Hospital, Lund University, Malmö, Sweden
Search for other papers by Pirkko Härkönen in
Google Scholar
PubMed
development of benign prostatic hyperplasia (BPH) and prostate cancer ( Härkönen & Mäkelä 2004 , Prins & Korach 2008 , Ellem & Risbridger 2009 , Hartman et al . 2012 ). In target tissues, estrogens act via estrogen receptor α (ERα) (ESR1) and ERβ (ESR2
A L Chand
A L Chand
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Search for other papers by A L Chand in
Google Scholar
PubMed
Search for other papers by A L Chand in
Google Scholar
PubMed
K A Herridge
K A Herridge
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Search for other papers by K A Herridge in
Google Scholar
PubMed
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Search for other papers by K A Herridge in
Google Scholar
PubMed
E W Thompson
E W Thompson
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Search for other papers by E W Thompson in
Google Scholar
PubMed
Search for other papers by E W Thompson in
Google Scholar
PubMed
C D Clyne
C D Clyne
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Search for other papers by C D Clyne in
Google Scholar
PubMed
Cancer Drug Discovery Laboratory, Department of Biochemistry, Invasion and Metastasis Laboratory, Prince Henry's Institute, 246 Clayton Road, Melbourne, Victoria 3168, Australia
Search for other papers by C D Clyne in
Google Scholar
PubMed
also an ERα target gene ( Annicotte et al . 2005 ) in MCF-7 cells. To determine whether LRH-1-dependent cell migration occurs independently of oestrogen, we repeated these experiments using the ER-negative MDA-MB-231 cell line and obtained similar
Amanda Schech
Amanda Schech
Department of Pharmacology, Division of Biostatistics, Department of Medicine and Physiology, University of Maryland School of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
Search for other papers by Amanda Schech in
Google Scholar
PubMed
Search for other papers by Amanda Schech in
Google Scholar
PubMed
Stephen Yu
Stephen Yu
Department of Pharmacology, Division of Biostatistics, Department of Medicine and Physiology, University of Maryland School of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
Search for other papers by Stephen Yu in
Google Scholar
PubMed
Search for other papers by Stephen Yu in
Google Scholar
PubMed
Olga Goloubeva
Olga Goloubeva
Department of Pharmacology, Division of Biostatistics, Department of Medicine and Physiology, University of Maryland School of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
Search for other papers by Olga Goloubeva in
Google Scholar
PubMed
Search for other papers by Olga Goloubeva in
Google Scholar
PubMed
John McLenithan
John McLenithan
Department of Pharmacology, Division of Biostatistics, Department of Medicine and Physiology, University of Maryland School of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
Search for other papers by John McLenithan in
Google Scholar
PubMed
Search for other papers by John McLenithan in
Google Scholar
PubMed
Gauri Sabnis
Gauri Sabnis
Department of Pharmacology, Division of Biostatistics, Department of Medicine and Physiology, University of Maryland School of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, USA
Search for other papers by Gauri Sabnis in
Google Scholar
PubMed
Search for other papers by Gauri Sabnis in
Google Scholar
PubMed
418 were obtained from Life Technologies. Human insulin and Matrigel were obtained from Sigma Chemical Company. Antibodies against phospho-ERα (S118 and S167) were purchased from Millipore (Billerica, MA, USA). Antibodies against p-Akt and Akt were
Nathan R West
Nathan R West
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Search for other papers by Nathan R West in
Google Scholar
PubMed
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Search for other papers by Nathan R West in
Google Scholar
PubMed
Leigh C Murphy
Leigh C Murphy
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Search for other papers by Leigh C Murphy in
Google Scholar
PubMed
Search for other papers by Leigh C Murphy in
Google Scholar
PubMed
Peter H Watson
Peter H Watson
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Search for other papers by Peter H Watson in
Google Scholar
PubMed
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Deeley Research Centre, Department of Biochemistry and Microbiology, Department of Biochemistry and Medical Genetics, Department of Pathology and Laboratory Medicine, BC Cancer Agency, 2410 Lee Avenue, 3rd Floor Research, Victoria, British Columbia, Canada V8R 6V5
Search for other papers by Peter H Watson in
Google Scholar
PubMed
Introduction Oestrogen receptor alpha (ERα) is a central factor in breast cell biology and growth. As the primary transcription factor that mediates oestrogen signalling, ER is the linchpin of endocrine therapy and a feature that partly defines the
Claudia Lanari
Claudia Lanari
Instituto de Biología y Medicina Experimental (IBYME‐CONICET), Oral and Pharyngeal Cancer Branch, Buenos Aires, Argentina
Search for other papers by Claudia Lanari in
Google Scholar
PubMed
Search for other papers by Claudia Lanari in
Google Scholar
PubMed
Victoria Wargon
Victoria Wargon
Instituto de Biología y Medicina Experimental (IBYME‐CONICET), Oral and Pharyngeal Cancer Branch, Buenos Aires, Argentina
Search for other papers by Victoria Wargon in
Google Scholar
PubMed
Search for other papers by Victoria Wargon in
Google Scholar
PubMed
Paola Rojas
Paola Rojas
Instituto de Biología y Medicina Experimental (IBYME‐CONICET), Oral and Pharyngeal Cancer Branch, Buenos Aires, Argentina
Search for other papers by Paola Rojas in
Google Scholar
PubMed
Search for other papers by Paola Rojas in
Google Scholar
PubMed
Alfredo A Molinolo
Alfredo A Molinolo
Instituto de Biología y Medicina Experimental (IBYME‐CONICET), Oral and Pharyngeal Cancer Branch, Buenos Aires, Argentina
Search for other papers by Alfredo A Molinolo in
Google Scholar
PubMed
Search for other papers by Alfredo A Molinolo in
Google Scholar
PubMed
express estrogen receptor alpha (ERα) and respond to antiestrogen therapies. These carcinomas may also express progesterone receptors (PRs), which are a reliable marker of functional ERs ( Kastner et al . 1990 , Petz & Nardulli 2000 ). In this paper, we
Carol A Lange
Carol A Lange
Departments of Medicine and Pharmacology, Masonic Cancer Center, University of Minnesota, 420 Delaware Street South East, MMC 806, Minneapolis Minnesota 55455, USA
Search for other papers by Carol A Lange in
Google Scholar
PubMed
Search for other papers by Carol A Lange in
Google Scholar
PubMed
Douglas Yee
Douglas Yee
Departments of Medicine and Pharmacology, Masonic Cancer Center, University of Minnesota, 420 Delaware Street South East, MMC 806, Minneapolis Minnesota 55455, USA
Search for other papers by Douglas Yee in
Google Scholar
PubMed
Search for other papers by Douglas Yee in
Google Scholar
PubMed
transcriptional upregulation of cyclin D1 mRNA and protein expression ( Prall et al . 1998 ). In addition, membrane-associated ERα molecules induce rapid activation of c-Src and MAPKs and are capable of transactivation of epidermal growth factor (EGFR) in breast
Yumi Endo
Yumi Endo
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Yumi Endo in
Google Scholar
PubMed
Search for other papers by Yumi Endo in
Google Scholar
PubMed
Tatsuya Toyama
Tatsuya Toyama
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Tatsuya Toyama in
Google Scholar
PubMed
Search for other papers by Tatsuya Toyama in
Google Scholar
PubMed
Satoru Takahashi
Satoru Takahashi
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Satoru Takahashi in
Google Scholar
PubMed
Search for other papers by Satoru Takahashi in
Google Scholar
PubMed
Nobuyasu Yoshimoto
Nobuyasu Yoshimoto
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Nobuyasu Yoshimoto in
Google Scholar
PubMed
Search for other papers by Nobuyasu Yoshimoto in
Google Scholar
PubMed
Mai Iwasa
Mai Iwasa
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Mai Iwasa in
Google Scholar
PubMed
Search for other papers by Mai Iwasa in
Google Scholar
PubMed
Tomoko Asano
Tomoko Asano
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Tomoko Asano in
Google Scholar
PubMed
Search for other papers by Tomoko Asano in
Google Scholar
PubMed
Yoshitaka Fujii
Yoshitaka Fujii
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Yoshitaka Fujii in
Google Scholar
PubMed
Search for other papers by Yoshitaka Fujii in
Google Scholar
PubMed
Hiroko Yamashita
Hiroko Yamashita
Departments of Oncology, Experimental Pathology and Tumor Biology, Immunology and Surgery
Search for other papers by Hiroko Yamashita in
Google Scholar
PubMed
Search for other papers by Hiroko Yamashita in
Google Scholar
PubMed
Introduction There are large-scale molecular differences between estrogen receptor α (ERα)-positive and ER-negative breast cancers ( Sorlie et al . 2003 ). ER is essential for estrogen-dependent growth, and its level of expression is a crucial
Vera Cappelletti
Vera Cappelletti
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Vera Cappelletti in
Google Scholar
PubMed
Search for other papers by Vera Cappelletti in
Google Scholar
PubMed
Manuela Gariboldi
Manuela Gariboldi
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Manuela Gariboldi in
Google Scholar
PubMed
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Manuela Gariboldi in
Google Scholar
PubMed
Loris De Cecco
Loris De Cecco
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Loris De Cecco in
Google Scholar
PubMed
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Loris De Cecco in
Google Scholar
PubMed
Sara Toffanin
Sara Toffanin
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Sara Toffanin in
Google Scholar
PubMed
Search for other papers by Sara Toffanin in
Google Scholar
PubMed
James F Reid
James F Reid
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by James F Reid in
Google Scholar
PubMed
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by James F Reid in
Google Scholar
PubMed
Lara Lusa
Lara Lusa
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Lara Lusa in
Google Scholar
PubMed
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Lara Lusa in
Google Scholar
PubMed
Emilio Bajetta
Emilio Bajetta
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Luigi Celio
Luigi Celio
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Luigi Celio in
Google Scholar
PubMed
Search for other papers by Luigi Celio in
Google Scholar
PubMed
Marco Greco
Marco Greco
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Marco Greco in
Google Scholar
PubMed
Search for other papers by Marco Greco in
Google Scholar
PubMed
Alessandra Fabbri
Alessandra Fabbri
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Alessandra Fabbri in
Google Scholar
PubMed
Search for other papers by Alessandra Fabbri in
Google Scholar
PubMed
Marco A Pierotti
Marco A Pierotti
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Marco A Pierotti in
Google Scholar
PubMed
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Marco A Pierotti in
Google Scholar
PubMed
Maria Grazia Daidone
Maria Grazia Daidone
Department of Experimental Oncology, Molecular Cancer Genetics, Departments of Medical Oncology, Surgery, Pathology, Scientific Direction, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milano, Italy
Search for other papers by Maria Grazia Daidone in
Google Scholar
PubMed
Search for other papers by Maria Grazia Daidone in
Google Scholar
PubMed
This study aimed to define a gene expression profile associated with response to anti-estrogen treatment in estrogen receptor α (ERα)-positive breast cancer from elderly patients and to identify possible candidate genes associated with resistance by detecting those modulated by treatment. Using cDNA microarrays containing 16 702 unique clones, 21 pre-treatment and 11 paired post-treatment samples collected in a neo-adjuvant toremifene trial on elderly patients with operable and locally advanced ERα-positive breast cancer were profiled. Gene expression profiles generated from pre-treatment samples were correlated with treatment-induced tumor shrinkage and compared with those obtained from post-treatment paired samples to define genes differentially modulated following anti-estrogen treatment. Correlation analysis on 21 pre-treatment samples highlighted 53 genes significantly related to treatment response (P<0.001). Genes involved in cell cycle and proliferation were more frequently upregulated in responders compared with non-responders. Class comparison analysis identified 101 genes significantly modulated independently of treatment response; 82 genes were modulated in non-responders, whereas only 8 genes were differently expressed after treatment in responders. Gene expression profiles appear to be more frequently modulated by anti-estrogen treatment in non-responding patients and may harbor interesting genes possibly involved in anti-estrogen resistance, including clusterin, MAPK6, and MMP2. This concept was corroborated by in vitro studies showing that silencing of CLU restored toremifene sensitivity in the ER anti-estrogen-resistant breast cancer cell line T47D. Integration between neo-adjuvant therapy and transcriptional profiling has therefore the potential to identify therapeutic targets to be challenged for overcoming treatment resistance.
R I Nicholson
R I Nicholson
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
Search for other papers by R I Nicholson in
Google Scholar
PubMed
Search for other papers by R I Nicholson in
Google Scholar
PubMed
C Staka
C Staka
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
Search for other papers by C Staka in
Google Scholar
PubMed
Search for other papers by C Staka in
Google Scholar
PubMed
F Boyns
F Boyns
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
Search for other papers by F Boyns in
Google Scholar
PubMed
Search for other papers by F Boyns in
Google Scholar
PubMed
I R Hutcheson
I R Hutcheson
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
Search for other papers by I R Hutcheson in
Google Scholar
PubMed
Search for other papers by I R Hutcheson in
Google Scholar
PubMed
J M W Gee
J M W Gee
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
Search for other papers by J M W Gee in
Google Scholar
PubMed
Search for other papers by J M W Gee in
Google Scholar
PubMed
deprivation provides an effective therapeutic second line strategy in advanced postmenopausal estrogen receptor positive (ERα+) breast cancer ( Johnston & Dowsett 2003 ). Moreover, emerging trial data indicate that AIs may be superior to the antiestrogen
R A Stein
R A Stein
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
Search for other papers by R A Stein in
Google Scholar
PubMed
Search for other papers by R A Stein in
Google Scholar
PubMed
D P McDonnell
D P McDonnell
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
Search for other papers by D P McDonnell in
Google Scholar
PubMed
Search for other papers by D P McDonnell in
Google Scholar
PubMed
Introduction Drugs that function by inhibiting ERα signaling have been and will continue to be an important part of pharmacotherapy in breast cancer. Foremost among these therapies are selective estrogen receptor modulators (SERMs
